Celltrion and Genewave Enter Antibody New Drug Joint Research and Development Partnership

Antibody Discovery and New Drug Development Promotion

Celltrion announced on the 14th that it has signed a joint research and development agreement with domestic new drug developer Genuv to promote antibody discovery and new drug development.

Incheon Songdo Celltrion Plant 2 Overview. / Incheon - Photo by Hyunmin Kim kimhyun81@

Under this agreement, once Genuv's preceding antibody discovery service is completed, the two companies will officially begin joint research for the discovery and development of up to two antibodies using Genuv's antibody discovery platform, "ShineMouse." Depending on the results of the joint research, if Celltrion exercises the license-in option, development milestones per antibody will be paid to Genuv up to 33 billion KRW, and sales milestones up to 900 billion KRW will be paid upon achieving cumulative sales of 10 trillion KRW after commercialization.

Genuv, established in 2016, is a domestic biotech company focusing on the development of neurological disease and immuno-oncology drugs. It owns its own single B cell isolation antibody discovery platform and immune-enhanced mouse "ShineMouse." In particular, it has discovered and developed multiple antibodies, including the anti-PD-1 antibody similar to Keytruda. Celltrion's strategy is to explore the possibility of developing high value-added new drugs through collaboration with Genuv, which possesses technology to secure various antibodies through mice.

In addition to its core business of antibody biosimilars, Celltrion is also securing new growth engines such as new drug development through in-house development and open innovation. To this end, it is expanding partnerships with various domestic and international bio companies. In particular, it plans to strengthen technology acquisition and product development in next-generation new drug fields such as antibody drugs, antibody-drug conjugates (ADC), bispecific antibodies, oncolytic viruses, and microbiomes, which are high value-added antibody-based new drugs.

A Celltrion official stated, "We plan to actively cooperate with promising bio companies like Genuv to maximize synergy in new drug development, not just utilizing our own antibody technology and know-how."

This content was produced with the assistance of AI translation services.